Search Results

There are 12373 results for: content related to: MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis

  1. You have free access to this content
    Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

    European Journal of Clinical Investigation

    Volume 41, Issue 10, October 2011, Pages: 1133–1148, Ann I. McCormack, John A. H. Wass and Ashley B. Grossman

    Version of Record online : 18 APR 2011, DOI: 10.1111/j.1365-2362.2011.02520.x

  2. You have free access to this content
    O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide


    Volume 118, Issue 18, 15 September 2012, Pages: 4545–4554, Emmanuèle Lechapt-Zalcman, Guénaëlle Levallet, Audrey Emmanuelle Dugué, Anne Vital, Marie-Danièle Diebold, Philippe Menei, Philippe Colin, Philippe Peruzzy, Evelyne Emery, Myriam Bernaudin, Françoise Chapon and Jean-Sébastien Guillamo

    Version of Record online : 22 FEB 2012, DOI: 10.1002/cncr.27441

  3. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

    Pediatric Blood & Cancer

    Volume 48, Issue 4, April 2007, Pages: 403–407, Andrew M. Donson, Steven O. Addo-Yobo, Michael H. Handler, Lia Gore and Nicholas K. Foreman

    Version of Record online : 11 APR 2006, DOI: 10.1002/pbc.20803

  4. You have free access to this content
    Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents

    Journal of Neurochemistry

    Volume 123, Issue 3, November 2012, Pages: 428–436, Monika Szeliga, Agata Zgrzywa, Marta Obara-Michlewska and Jan Albrecht

    Version of Record online : 21 SEP 2012, DOI: 10.1111/j.1471-4159.2012.07917.x

  5. You have free access to this content
    Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

    Clinical Endocrinology

    Volume 76, Issue 6, June 2012, Pages: 769–775, Gérald Raverot, Frédéric Castinetti, Emmanuel Jouanneau, Isabelle Morange, Dominique Figarella-Branger, Henry Dufour, Jacqueline Trouillas and Thierry Brue

    Version of Record online : 23 APR 2012, DOI: 10.1111/j.1365-2265.2012.04381.x

  6. You have free access to this content
    Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

    CA: A Cancer Journal for Clinicians

    Volume 60, Issue 3, May/June 2010, Pages: 166–193, Erwin G. Van Meir, Costas G. Hadjipanayis, Andrew D. Norden, Hui-Kuo Shu, Patrick Y. Wen and Jeffrey J. Olson

    Version of Record online : 5 MAY 2010, DOI: 10.3322/caac.20069

  7. You have free access to this content
    Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O6-methylguanine DNA methyltransferase expression

    British Journal of Haematology

    Volume 167, Issue 5, December 2014, Pages: 664–670, Joseph M. Brandwein, Jeannine Kassis, Brian Leber, Donna Hogge, Kang Howson-Jan, Mark D. Minden, André Galarneau and Jean-François Pouliot

    Version of Record online : 27 AUG 2014, DOI: 10.1111/bjh.13094

  8. You have free access to this content
    Treatment of pituitary neoplasms with temozolomide


    Volume 117, Issue 3, 1 February 2011, Pages: 454–462, Luis V. Syro, Leon D. Ortiz, Bernd W. Scheithauer, Ricardo Lloyd, Queenie Lau, Ricardo Gonzalez, Humberto Uribe, Michael Cusimano, Kalman Kovacs and Eva Horvath

    Version of Record online : 15 SEP 2010, DOI: 10.1002/cncr.25413

  9. You have free access to this content
    Temozolomide for high grade glioma

    Intervention Review

    The Cochrane Library

    Michael G Hart, Ruth Garside, Gabriel Rogers, Ken Stein and Robin Grant

    Published Online : 30 APR 2013, DOI: 10.1002/14651858.CD007415.pub2

  10. You have free access to this content
    MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma

    International Journal of Cancer

    Volume 136, Issue 12, 15 June 2015, Pages: 2844–2853, Rainer Tuominen, Rosalyn Jewell, Joost J. van den Oord, Pascal Wolter, Ulrika Stierner, Christer Lindholm, Carolina Hertzman Johansson, Diana Lindén, Hemming Johansson, Marianne Frostvik Stolt, Christy Walker, Helen Snowden, Julia Newton-Bishop, Johan Hansson and Suzanne Egyházi Brage

    Version of Record online : 24 NOV 2014, DOI: 10.1002/ijc.29332

  11. You have free access to this content
    Dose-dense temozolomide regimens


    Volume 116, Issue 12, 15 June 2010, Pages: 2868–2877, Bart Neyns, Alicia Tosoni, Wen-Jen Hwu and David A. Reardon

    Version of Record online : 29 MAR 2010, DOI: 10.1002/cncr.25035

  12. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

    Clinical Endocrinology

    Volume 71, Issue 2, August 2009, Pages: 226–233, Ann I. McCormack, Kerrie L. McDonald, Anthony J. Gill, Susan J. Clark, Morton G. Burt, Kirsten A. Campbell, Wilton J. Braund, Nicholas S. Little, Raymond J. Cook, Ashley B. Grossman, Bruce G. Robinson and Roderick J. Clifton-Bligh

    Version of Record online : 3 DEC 2008, DOI: 10.1111/j.1365-2265.2008.03487.x

  13. You have free access to this content
    MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome

    International Journal of Cancer

    Volume 122, Issue 6, 15 March 2008, Pages: 1391–1399, Dorothee Wiewrodt, Georg Nagel, Nadine Dreimüller, Thomas Hundsberger, Axel Perneczky and Bernd Kaina

    Version of Record online : 13 NOV 2007, DOI: 10.1002/ijc.23219

  14. CNS Cancers

    Standard Article

    Burger's Medicinal Chemistry and Drug Discovery

    Robertson Graeme

    Published Online : 15 SEP 2010, DOI: 10.1002/0471266949.bmc223

  15. Temozolomide in the management of dopamine agonist–resistant prolactinomas

    Clinical Endocrinology

    Volume 76, Issue 6, June 2012, Pages: 877–886, B. C. Whitelaw, D. Dworakowska, N. W. Thomas, S. Barazi, P. Riordan-Eva, A. P. King, T. Hampton, D. B. Landau, D. Lipscomb, C. R. Buchanan, J. A. Gilbert and S. J. B. Aylwin

    Version of Record online : 23 APR 2012, DOI: 10.1111/j.1365-2265.2012.04373.x

  16. The P140K mutant of human O6-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O6-(4-bromothenyl)guanine

    The Journal of Gene Medicine

    Volume 8, Issue 1, January 2006, Pages: 29–34, Lorna B. Woolford, Thomas D. Southgate, Geoffrey P. Margison, Michael D. Milsom and Leslie J. Fairbairn

    Version of Record online : 1 AUG 2005, DOI: 10.1002/jgm.816

  17. You have free access to this content
    SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

    International Journal of Cancer

    Volume 135, Issue 11, 1 December 2014, Pages: 2711–2720, Julien Hadoux, Judith Favier, Jean-Yves Scoazec, Sophie Leboulleux, Abir Al Ghuzlan, Caroline Caramella, Désirée Déandreis, Isabelle Borget, Céline Loriot, Cécile Chougnet, Eric Letouzé, Jacques Young, Laurence Amar, Jérome Bertherat, Rosella Libé, Frédéric Dumont, Frédéric Deschamps, Martin Schlumberger, Anne Paule Gimenez-Roqueplo and Eric Baudin

    Version of Record online : 5 MAY 2014, DOI: 10.1002/ijc.28913

  18. You have free access to this content
    Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

    British Journal of Pharmacology

    Volume 169, Issue 8, August 2013, Pages: 1745–1765, N J Curtin

    Version of Record online : 26 JUL 2013, DOI: 10.1111/bph.12244

  19. You have free access to this content
    O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study

    International Journal of Cancer

    Volume 88, Issue 3, 1 November 2000, Pages: 469–473, Mark R. Middleton, Siow M. Lee, Ana Arance, Michelle Wood, Nicholas Thatcher and Geoffrey P. Margison

    Version of Record online : 17 OCT 2000, DOI: 10.1002/1097-0215(20001101)88:3<469::AID-IJC21>3.0.CO;2-7

  20. You have free access to this content
    Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

    International Journal of Cancer

    Volume 131, Issue 6, 15 September 2012, Pages: 1342–1350, Guido Reifenberger, Bettina Hentschel, Jörg Felsberg, Gabriele Schackert, Matthias Simon, Oliver Schnell, Manfred Westphal, Wolfgang Wick, Torsten Pietsch, Markus Loeffler, Michael Weller and for the German Glioma Network

    Version of Record online : 11 JAN 2012, DOI: 10.1002/ijc.27385